Inhibition of Tumor Progression and Paraneoplastic Syndrome Development in a Murine Lung Adenocarcinoma by Medroxyprogesterone Acetate and Indomethacin

REFERENCES

• Tisdale M. J. Biology of cachexia. J. Natl. Cancer Inst. 1997; 89: 1763–1773, [CSA]
   PubMed Web of Science ®Google Scholar
• Nelson K. A. The cancer anorexia-cachexia syndrome. Semin. Oncol. 2000; 27: 64–68, [CSA]
   PubMed Web of Science ®Google Scholar
• Argilés J. M., Alvarez B., Lopez-Soriano F. J. The metabolic basis of cancer cachexia. Med. Res. Rev. 1997; 17(5)477–498, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Costelli P., Carbo N., Tessitore L., Bagby G. J., Lopez-Soriano F. J., Argiles J. M., Baccino F. M. Tumor necrosis factor α mediate changes in tissue protein turnover in a rat cancer cachexia model. J. Clin. Invest. 1993; 92: 2783–2789, [CSA]
   PubMed Web of Science ®Google Scholar
• Gelin J., Moldawer L. L., Lonnroth C. Role of endogenous tumor necrosis factor α and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res. 1991; 51: 415–421, [CSA]
   PubMed Web of Science ®Google Scholar
• Strassman G., Fong M., Kenney J. S., Jacob C. A. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 1992; 89: 1681–1684, [CSA]
   PubMed Web of Science ®Google Scholar
• Falconer S. J., Fearon K. C.H., Plester C. E. Cytokines, the acute-phase response and resting energy expenditure in cachectic patients with pancreatic cancer. Ann. Surg. 1994; 219: 325–331, [CSA]
   PubMed Web of Science ®Google Scholar
• Wigmore S. J., Falconer J. S., Plester C. E., Ross J. A., Maingay J. P., Carter D. C., Fearon K. H.C. Ibuprofen reduces energy expenditure and acute phase protein production in pancreatic cancer patients compared with placebo. Br. J. Cancer 1995; 72(1)185–188, [CSA]
   PubMed Web of Science ®Google Scholar
• Staal-van d en, Brekel A. J., Dentener M. A., Schols A. M., Buurman W. A., Wouters E. F. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J. Clin. Oncol. 1995; 13(10)2600–2605, [CSA]
   PubMed Web of Science ®Google Scholar
• McMillan D. C., Leen E., Smith I., Sturgeon C. M., Preston T., Cooke T. C., McArdle C. S. Effect of extended ibuprofen administration on cortisol, interleukin 6 and the acute phase protein response in colorectal cancer patients. Eur. J. Surg. Oncol. 1995; 21: 531–534, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• McMillan D. C., Gorman P. O., Fearon K. C.H., McArdle C. S. A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br. J. Cancer 1997; 76(6)788–790, [CSA]
   PubMed Web of Science ®Google Scholar
• Maltoni M., Nanni O., Scarpi E., Rossi D., Serra P., Amadori D. High-dose progestins for the treatment of cancer anorexia/cachexia syndrome. A systemic review of randomized clinical trials. Ann. Oncol. 2001; 12: 289–300, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mantovani G., Maccio A., Lai P., Massa E., Ghiani M., Santona M. C. Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin. Oncol. 1998; 2(6)45–52, [CSA]
   Google Scholar
• Lelli G., Angelelli B., Giambiasi M. E., Colalongo F., Camaggi C. M., Costatnti B., Strocchi E., Pannuti F. The anabolic effect of high dose medroxyprogesterone acetate in oncology. Pharmacol. Res. Commun. 1983; 15: 561–568, [CSA]
   PubMedGoogle Scholar
• Cavalli F., Goldhirsch A., Jungi F., Martz G., Mermillod B., Alberto P. Randomized trial of low versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J. Clin. Oncol. 1984; 2: 414–419, [CSA]
   PubMed Web of Science ®Google Scholar
• Cerchietti L. C.A., Navigante A. H., Peluffo G. D., Diament M. J., Stillitani I., Klein S. A., Cabalar M. E. Effects of celecoxib, medroxyprogesterone and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. J. Pain Symptom. Manage. 2004; 27(1)85–95, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Diament M., Garcia C., Stillitani I., Muñiz Saavedra V., Manzur T., Vauthay L., Klein S. Spontaneous murine lung adenocarcinoma (P07): a new experimental model to study paraneoplastic syndromes of lung cancer. Int. J. Mol. Med. 1998; 2: 45–50, [CSA]
   PubMed Web of Science ®Google Scholar
• Diament M. J., García C., Parma M., Mondelo N., Stillitani I., Klein S. M. Immune reactivity during growth of a murine lung adenocarcinoma: evaluation of paraneoplastic syndrome development. Oncol. Rep. 2001; 8(5)1165–1170, [CSA]
   PubMed Web of Science ®Google Scholar
• Parma M., Diament M., García C., Piccinni E., Mondelo N., Klein S. Mechanisms of paraneoplastic syndromes in mice bearing a spontaneous lung adenocarcinoma. Tumor Biol. 1999; 20: 304–311, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Peluffo G. D., Stillitani I., Rodríguez V. A., Diament M. J., Klein S. M. Reduction of tumor progression and paraneoplastic development of a murine lung adenocarcinoma by non steroidal antiinflammatory drugs. Int. J. Cancer 2004; 110(6)825–830, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Urtreger A. L., Diament M. J., Ranuncolo S. M., Vidal M. C., Puricelli L. I., Klein S. M., Bal de Kier Joffé E. D. A new murine cell line derived from a spontaneous lung tumor induces paraneoplastic syndromes. Int. J. Oncol. 2001; 18: 639–647, [CSA]
   PubMed Web of Science ®Google Scholar
• Abe M., Yamashita J., Ogawa M. Medroxyprogesterone acetate inhibits human pancreatic carcinoma cell growth by inducing apoptosis in association with Bcl-2 phosphorylation. Cancer 2000; 88(9)2000–2009, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ranuncolo S. M., Armanasco E., Cresta C., Bal de Kier Joffé E. D., Puricelli L. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and the assesment of prognosis in breast cancer patients. Int. J. Cancer 2003; 106(5)745–751, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Di Nezza L. A., Jobling T., Salamonsen L. A. Progestin suppress matrix metalloproteinases production in endometrial cancer. Gynecol. Oncol. 2003; 89(2)325–333, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Attiga F. A., Fernández P. M., Weeraratna A. T., Manyak M. J., Patierno S. R. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. 2000; 60: 4629–4637, [CSA]
   PubMed Web of Science ®Google Scholar
• McNamara M. J., Alexander R., Norton J. A. Cytokines and their role in the pathophysiology of cancer cachexia. J. Parenter. Enteral Nutr. 1992; 16(6)50S–55S, [CSA]
   PubMed Web of Science ®Google Scholar
• Zhang G. H., Adachi I. Serum Interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 1999; 79: 1427–1432, [CSA]
   Google Scholar
• Kurebayashi J., Yamamoto S., Otsuki T., Sonoo H. Medroxiprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect. Br. J. Cancer 1999; 631–636, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mantovani G., Macció A., Lai P., Massa E., Massa D., Mulas C., Succu G., Mudu M. C., Manca G., Versace R., Pisano M. Results of a dose-intense phase 1 study of a combination chemotherapy regimen with cisplatin and epidoxorubicin including medroxyprogesterone acetate and recombinant interleukin-2 in patients with inoperable primary lung cancer. J. Immunoth. 2000; 23(2)267–274, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Trayhurn P., Beattie J. H. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc. Nutr. Soc. 2001; 60: 329–339, [CSA]
   PubMed Web of Science ®Google Scholar
• García-Martinez C., Lopez Soriano F. J., Argilés J. M. Interleukin-6 does not active protein breakdown in rat skeletal muscle. Cancer Lett. 1994; 76(1)1–4, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Apte R. N., Voronov E. Interleukin-1-a major pleiotropic cytokine in tumor-host interactions. Semin. Cancer Biol. 2002; 12: 277–290, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cassatella M. A. The production of cytokines by polymorphonuclear neutrophils. Immunol. Today 1995; 16(1)21–26, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Arlt A., Schafer H. NFkappaB-dependent chemoresistance in solid tumors. Int. Clin. Pharmacol. Ther. 2004; 40: 336–347, [CSA]
   Web of Science ®Google Scholar
• Lundholm K., Daneryd P., Korner U., Hyltander A., Bosaeus I. Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int. J. Oncol. 2004; 24(3)505–512, [CSA]
   PubMed Web of Science ®Google Scholar
• Lehmann J. M., Lenhard J. M., Oliver B. B., Ringold G. M., Kliewer S. A. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 1997; 272: 3406–3410, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar